Clinical Trial Update: A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) [Phase 3]

View source ↗

Summary

Safety extension results from a Phase 3 trial of ontamalimab in moderate to severe Crohn's disease or ulcerative colitis have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Ontamalimab (ontamalimab)

Snippet

Sponsor: Shire | Conditions: Crohn's Disease, Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2024-06-21